Itinai.com biomedical laboratory close up still scene close u 2a5a1238 15e1 44d7 ad99 fe42b30c4e72 0
Itinai.com biomedical laboratory close up still scene close u 2a5a1238 15e1 44d7 ad99 fe42b30c4e72 0

Exploring therapeutic mechanisms of Chuan Huang Fang-II in the treatment of acute kidney injury on chronic kidney disease patients from the perspective of lipidomics

Exploring Therapeutic Mechanisms of Chuan Huang Fang-II in the Treatment of Acute Kidney Injury on Chronic Kidney Disease Patients

Study Information

Journal: Ren Fail. 2024 Dec;46(1):2356021

DOI: 10.1080/0886022X.2024.2356021

Date: Epub 2024 May 24

Objective

This study evaluates the effectiveness and safety of CHF-II combined with RG for treating AKI on CKD (A on C) and investigates potential therapeutic mechanisms through lipidomics analysis.

Methods

98 patients were randomly assigned to the RG or RG + CHF groups. Both groups received RG therapy, with the RG + CHF group also receiving CHF-II treatment for two weeks. Evaluation endpoints included changes in renal function, blood lipid profiles, urinary AKI biomarkers, and TCM symptoms before and after treatment. Serum samples were collected for lipid metabolite analysis.

Results

The clinical effective rate in the RG + CHF group was 73.5%, compared to 40.8% in the RG group. TCM syndrome scores in the RG + CHF group showed a more pronounced decrease. Both groups showed improvements in renal function and lipid profiles, with greater improvements observed in the RG + CHF group. Urinary AKI biomarkers decreased more in the RG + CHF group. No serious adverse events occurred during the trial. 58 different lipid metabolites and 48 lipid biomarkers were identified, suggesting possible metabolic pathways involved in the therapeutic action of CHF-II.

Conclusion

CHF-II effectively alleviated kidney injury and improved TCM syndrome scores in patients with A on C. Lipid differential metabolites could serve as diagnostic indicators for AKI in patients with CKD. The possible metabolic pathways might be implicated in the therapeutic action of CHF-II in the prevention and treatment of patients with A on C.

Practical Solutions and Value

Clinical trials are vital for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into an easily accessible knowledge base for clinicians. In today’s healthcare environment, streamlining operations is crucial. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally. By using AI, clinics can enhance their workflows and improve patient outcomes, reducing paper routines. Learn more about how we can help at aidevmd.com.

AI-Powered Health Tools

Interactive AI Tools to Help You Understand Your Health

Solutions for Smart Healthcare

Clinical Research